MEI Pharma, Inc.

247 articles with MEI Pharma, Inc.

• MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies

  10/3/2019

  MEI Pharma, Inc. announced updated data from the ongoing Phase 1b study of investigational ME-401, a selective oral inhibitor of PI3K delta.

• MEI Pharma to Host Investor and Analyst Event on October 4, 2019

  9/23/2019

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled "A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies."

• MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference

  8/29/2019

  MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 2019 Wells Fargo Global Healthcare Conference

• MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights

  8/28/2019

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2019.

• MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019

  8/21/2019

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2019 fiscal year end financial results after the close of the U.S. financial markets on August 28, 2019.

• MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors

  7/3/2019

  Ms. Howson is a highly experienced business development executive and consultant with more than 30 years of service in the pharmaceutical and biotechnology industries.

• MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

  6/22/2019

  83% overall response rate in patients with relapsed or refractory follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma

• MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  6/3/2019

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced that updated data presented at ASCO 2019 from a Phase 1b study of investigational ME-401, a selective oral inhibitor of PI3K delta, demonstrate an 80% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) (n= 50)

• MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  6/1/2019

  Statistically significant biologic anti-tumor activity demonstrated as measured by a reduction in Ki67 in patients treated with ME-344 compared to an increase in patients receiving placebo

• MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference

  5/31/2019

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 1:00 p.m. ET.

• MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/15/2019

  MEI Pharma, Inc. announced the publication of data abstracts related to two of MEI Pharma's clinical stage drug development programs to be presented at the 2019 ASCO Annual Meeting to be held May 31 to June 4, 2019 in Chicago.

• MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights

  5/9/2019

  MEI Pharma, Inc. reported results for its third quarter ended March 31, 2019.

• MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights

  2/7/2019

  MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval

• Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

  12/3/2018

  Helsinn Group and MEI Pharma, Inc. today announced interim data from a Phase 2 study evaluating pracinostat, a histone deacetylase inhibitor, in combination with azacitidine for the treatment of patients with IPSS-R high/very high-risk of Myelodysplastic Syndrome (MDS).

• MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting

  12/2/2018

  Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients

• MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting

  12/1/2018

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting

• MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights

  11/8/2018

  MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End

• MEI Pharma To Present at Stifel 2018 Healthcare Conference

  11/6/2018

  MEI Pharma, Inc. today announced that Daniel P. Gold, Ph.D. will present a corporate update at the Stifel 2018 Healthcare Conference.

• MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan

  11/5/2018

  MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced the execution of a license agreement granting Kyowa Hakko Kirin exclusive rights to develop and commercialize ME-401 in Japan

• MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting

  11/1/2018

   MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present data from three accepted abstracts related to MEI Pharma's clinical stage drug development programs at the 2018 ASH Annual Meeting to be held December 1-4, 2018 in San Diego.